ACTG2

Across TCGA pan-cancer cohorts, ACTG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACTG2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACTG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACTG2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ACTG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.671	0.318	<.001	47	view →
LUAD	DFS	Median	All	0.878	0.955	.001	30	view →
CCRCC	DFS	Quartile	All	0.458	0.929	.003	18	view →
LSCC	DFS	Tertile	II,III,IV	0.464	0.885	.004	13	view →
HNSC	DFS	Median	IV	0.366	0.817	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACTG2–PDAC (OS)

Open the PDAC breakdown →